ORPHENADRINE CITRATE Drug Patent Profile
✉ Email this page to a colleague
When do Orphenadrine Citrate patents expire, and what generic alternatives are available?
Orphenadrine Citrate is a drug marketed by Hikma, Rising, Sagent Pharms, Watson Labs, Ascot, Lupin, Sandoz, Stevens J, and Unichem. and is included in fifteen NDAs.
The generic ingredient in ORPHENADRINE CITRATE is aspirin; caffeine; orphenadrine citrate. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aspirin; caffeine; orphenadrine citrate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ORPHENADRINE CITRATE?
- What are the global sales for ORPHENADRINE CITRATE?
- What is Average Wholesale Price for ORPHENADRINE CITRATE?
Summary for ORPHENADRINE CITRATE
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 15 |
| Finished Product Suppliers / Packagers: | 17 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 1 |
| Patent Applications: | 978 |
| Drug Prices: | Drug price information for ORPHENADRINE CITRATE |
| DailyMed Link: | ORPHENADRINE CITRATE at DailyMed |
Recent Clinical Trials for ORPHENADRINE CITRATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Baghdad | PHASE4 |
Pharmacology for ORPHENADRINE CITRATE
| Drug Class | Muscle Relaxant |
| Physiological Effect | Centrally-mediated Muscle Relaxation |
US Patents and Regulatory Information for ORPHENADRINE CITRATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma | ORPHENADRINE CITRATE | orphenadrine citrate | INJECTABLE;INJECTION | 040463-001 | Mar 4, 2003 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Lupin | ORPHENADRINE CITRATE | orphenadrine citrate | TABLET, EXTENDED RELEASE;ORAL | 040284-001 | Jun 19, 1998 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Watson Labs | ORPHENADRINE CITRATE | orphenadrine citrate | INJECTABLE;INJECTION | 084779-001 | Mar 15, 1982 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Unichem | ORPHENADRINE CITRATE | orphenadrine citrate | TABLET, EXTENDED RELEASE;ORAL | 091158-001 | Jul 27, 2012 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Rising | ORPHENADRINE CITRATE | orphenadrine citrate | TABLET, EXTENDED RELEASE;ORAL | 040249-001 | Jan 29, 1999 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
